small molecule

EVRYSDI

RISDIPLAM

Loss of exclusivityApril 2041latest FDA-listed patent expiry

CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand name	EVRYSDI
Active ingredient	RISDIPLAM
Strength	0.75MG/ML
Dosage form	FOR SOLUTION
Route	ORAL
Modality	Small molecule
FDA approval	August 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12122789	April 2041	substance, product
11534444	October 2038	use U-1943
12350273	October 2038	use U-1943
11938136	November 2036	product
11827646	January 2036	use U-1943
9969754	May 2035	substance, product
9586955	February 2033	substance, product

Regulatory exclusivity

Code	Expires
ODE-400	May 2029
ODE-334	August 2027
M-270	October 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Genentech